AU651711B2 - A composition for the sustained and controlled release of medicamentous substances and a process for preparing the same - Google Patents

A composition for the sustained and controlled release of medicamentous substances and a process for preparing the same

Info

Publication number
AU651711B2
AU651711B2 AU20436/92A AU2043692A AU651711B2 AU 651711 B2 AU651711 B2 AU 651711B2 AU 20436/92 A AU20436/92 A AU 20436/92A AU 2043692 A AU2043692 A AU 2043692A AU 651711 B2 AU651711 B2 AU 651711B2
Authority
AU
Australia
Prior art keywords
sustained
preparing
composition
same
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU20436/92A
Other languages
English (en)
Other versions
AU2043692A (en
Inventor
Frederic Dr. Heimgartner
Piero Dr. Orsolini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Asta Medica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica GmbH filed Critical Asta Medica GmbH
Publication of AU2043692A publication Critical patent/AU2043692A/en
Assigned to ASTA MEDICA AKTIENGESELLSCHAFT reassignment ASTA MEDICA AKTIENGESELLSCHAFT Alteration of Name(s) of Applicant(s) under S113 Assignors: DEBIO RECHERCHE PHARMACEUTIQUE S.A.
Application granted granted Critical
Publication of AU651711B2 publication Critical patent/AU651711B2/en
Assigned to ZENTARIS AKTIENGESELLSCHAFT reassignment ZENTARIS AKTIENGESELLSCHAFT Alteration of Name(s) in Register under S187 Assignors: ASTA MEDICA AKTIENGESELLSCHAFT
Assigned to ZENTARIS GMBH reassignment ZENTARIS GMBH Request to Amend Deed and Register Assignors: ZENTARIS AKTIENGESELLSCHAFT
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU20436/92A 1991-07-22 1992-07-21 A composition for the sustained and controlled release of medicamentous substances and a process for preparing the same Ceased AU651711B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH2178/91 1991-07-22
CH2178/91A CH683149A5 (fr) 1991-07-22 1991-07-22 Procédé pour la préparation de microsphères en matériau polymère biodégradable.

Publications (2)

Publication Number Publication Date
AU2043692A AU2043692A (en) 1993-01-28
AU651711B2 true AU651711B2 (en) 1994-07-28

Family

ID=4227716

Family Applications (2)

Application Number Title Priority Date Filing Date
AU20436/92A Ceased AU651711B2 (en) 1991-07-22 1992-07-21 A composition for the sustained and controlled release of medicamentous substances and a process for preparing the same
AU20437/92A Expired AU652844B2 (en) 1991-07-22 1992-07-21 A process for the preparation of microspheres made of a biodegradable polymeric material

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU20437/92A Expired AU652844B2 (en) 1991-07-22 1992-07-21 A process for the preparation of microspheres made of a biodegradable polymeric material

Country Status (40)

Country Link
US (2) US5445832A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP2842736B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR930702018A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1054543C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) AT408609B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU651711B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (2) BE1005696A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9205375A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2074320C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (2) CH683149A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ287585B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE4223282A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK176219B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE03014B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2037621B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (2) FI105318B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (2) FR2679450B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (2) GB2257973B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (2) GR1001446B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP920229A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU218203B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (2) IE69967B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL102590A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (2) IT1259891B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (2) LU88151A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9204268A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (2) NL194577C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO304057B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ243643A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH31564A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL169387B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT100713B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2103994C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (2) SE512670C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI9200152B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK280612B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW260610B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA35569C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1993001802A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (2) ZA925485B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
CA2123144A1 (en) 1993-05-10 1994-11-11 David Bodmer Stabilisation of pharmacologically active compounds in sustained release compositions
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
DE4320201A1 (de) * 1993-06-18 1995-01-12 Asta Medica Ag Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
DE4342092B4 (de) * 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
EP0835101B1 (en) 1995-06-27 2004-06-09 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
KR0162872B1 (ko) * 1996-04-01 1998-12-01 김은영 용매추출법을 이용한 생분해성 고분자 미립구의 개선된 제조방법 및 이를 이용한 국소염증 질환 치료용 미립구의 제조방법
US20020111603A1 (en) * 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
AU5678398A (en) * 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
TW577759B (en) * 1997-04-18 2004-03-01 Ipsen Pharma Biotech Sustained release compositions in the form of microcapsules or implants and the process for their preparation
US6465015B1 (en) * 1998-02-24 2002-10-15 Arch Chemicals, Inc. Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
CA2324254C (en) * 1998-03-18 2005-01-04 University Technology Corporation Sustained-release composition including amorphous polymer
SE9801288D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
WO2000004916A1 (en) * 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation of water soluble peptides
US20070009605A1 (en) * 1998-07-23 2007-01-11 Ignatious Francis X Encapsulation of water soluble peptides
EP1240896A3 (en) * 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
JP2002521343A (ja) * 1998-07-23 2002-07-16 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス 水溶性ペプチドのカプセル化
US6270700B1 (en) 1998-07-23 2001-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Encapsulation of water soluble peptides
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
GB2344519B (en) * 1998-12-07 2004-05-19 Johnson & Johnson Medical Ltd Sterile therapeutic compositions
IT1304152B1 (it) * 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
US6682724B2 (en) 1999-02-23 2004-01-27 Arch Chemcials, Inc. Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
US6317623B1 (en) * 1999-03-12 2001-11-13 Medrad, Inc. Apparatus and method for controlling contrast enhanced imaging procedures
WO2000054797A2 (en) 1999-03-17 2000-09-21 Novartis Ag Pharmaceutical compositions comprising tgf-beta
EP1044683A1 (en) * 1999-04-15 2000-10-18 Debio Recherche Pharmaceutique S.A. One-step dispersion method for the microencapsulation of water soluble substances
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
ES2169980B1 (es) * 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
US6309454B1 (en) 2000-05-12 2001-10-30 Johnson & Johnson Medical Limited Freeze-dried composite materials and processes for the production thereof
US6899898B2 (en) 2000-12-21 2005-05-31 Nektar Therapeutics Induced phase transition method for the production of microparticles containing hydrophobic active agents
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
IL160570A0 (en) * 2001-09-26 2004-07-25 Baxter Int Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
KR100885070B1 (ko) * 2002-05-08 2009-02-25 재단법인서울대학교산학협력재단 Ｐｌｇａ에 특이적으로 부착하는 올리고 펩타이드
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
KR20050086948A (ko) * 2002-12-27 2005-08-30 디오벡스, 인코포레이티드 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
SI1594517T1 (sl) 2003-01-28 2007-10-31 Microbia Inc Sestavki za zdravljenje gastrointestinalnih motenj
EP1605894A2 (en) * 2003-03-05 2005-12-21 PR Pharmaceuticals Oxytocin controlled release formulations and methods of using same
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
CN105820160B (zh) 2003-11-05 2019-02-12 萨可德生物科学公司 细胞粘着调节剂
RU2393168C2 (ru) * 2004-07-19 2010-06-27 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
AU2005325213B2 (en) 2004-08-04 2010-10-07 Evonik Operations Gmbh Methods for manufacturing delivery devices and devices thereof
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006078903A1 (en) * 2005-01-21 2006-07-27 Matthews Richard H Radiosensitizer formulations comprising nitrohistidine derivatives
AU2006241072A1 (en) * 2005-04-25 2006-11-02 Amgen Inc. Biodegradable peptide sustained release compositions containing porogens
EP3195861A1 (en) 2005-05-17 2017-07-26 SARcode Bioscience Inc. Compositions and methods for treatment of dry eye disorders
MX2007015183A (es) * 2005-06-14 2008-02-19 Baxter Int Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco.
JP2009516003A (ja) * 2005-11-15 2009-04-16 バクスター・インターナショナル・インコーポレイテッド リポキシゲナーゼ阻害剤の組成物
KR20140133968A (ko) 2005-12-22 2014-11-20 노파르티스 아게 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
WO2007089739A2 (en) * 2006-01-27 2007-08-09 Stryker Corporation Low pressure delivery system and method for delivering a solid and liquid mixture into a target site for medical treatment
KR100722607B1 (ko) * 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
US7403325B2 (en) * 2006-05-19 2008-07-22 Xerox Corporation Electrophoretic display device
RU2326655C1 (ru) * 2006-11-09 2008-06-20 Федеральное государственное учреждение "48 Центральный научно-исследовательский институт Министерства обороны Российской Федерации" Способ инкапсулирования белоксодержащих веществ в микросферы из сополимера полилактид-полигликолид
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US20080293695A1 (en) * 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US7858663B1 (en) 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
US8211905B1 (en) 2007-05-22 2012-07-03 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8329720B1 (en) 2007-05-22 2012-12-11 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties
US10183001B1 (en) 2007-05-22 2019-01-22 Pisgah Laboratories, Inc. Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
US9421266B2 (en) 2007-05-22 2016-08-23 Pisgah Laboratories, Inc. Safety of pseudoephedrine drug products
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
CN103601792B (zh) 2007-06-04 2016-06-29 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US10166181B2 (en) * 2007-06-06 2019-01-01 Debiopharm Research & Manufacturing Sa Slow release pharmaceutical composition made of microgranules
PT2203181T (pt) 2007-10-16 2018-05-10 Biocon Ltd Uma composição farmacêutica sólida para administração por via oral e o seu processo de fabrico
CA2958665C (en) 2007-10-19 2021-03-02 Sarcode Bioscience Inc. Compositions and methods for treatment of diabetic retinopathy
EP2222281B1 (en) 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
US20090258069A1 (en) * 2008-04-15 2009-10-15 John Burnier Delivery of LFA-1 antagonists to the gastrointestinal system
US8080562B2 (en) * 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
US11612579B2 (en) 2009-03-09 2023-03-28 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
ES2363965B1 (es) 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
CN102665698A (zh) 2009-12-23 2012-09-12 迪菲安特制药有限责任公司 可用于治疗心血管疾病的联合组合物
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012151343A1 (en) 2011-05-04 2012-11-08 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
WO2013072767A1 (en) 2011-11-18 2013-05-23 Pronova Biopharma Norge As Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
WO2013150386A2 (en) 2012-04-04 2013-10-10 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
US9585896B2 (en) 2012-04-04 2017-03-07 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin D for psoriasis, and methods and uses thereof
PT2851085T (pt) * 2012-05-14 2019-10-11 Teijin Pharma Ltd Composição proteica esterilizada por radiação
JP6607780B2 (ja) 2012-07-25 2019-11-20 サルコード・バイオサイエンス・インコーポレイテッド Ｌｆａ−１阻害剤およびその多形
HK1218629A1 (zh) 2013-02-25 2017-03-03 Bausch Health Ireland Limited 用於结肠清洁的鸟苷酸环化酶受体激动剂
EP3578170A1 (en) 2013-02-28 2019-12-11 Basf As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
EP3054969B1 (en) 2013-10-10 2021-03-10 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
US20160151511A1 (en) 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
JP6784696B2 (ja) 2015-04-28 2020-11-11 プロノヴァ バイオファーマ ノルゲ エーエス 硫黄を含有する構造的に強化された脂肪酸の非アルコール性脂肪性肝炎の予防及び／又は治療のための使用
EP3402804A1 (en) 2016-01-11 2018-11-21 Synergy Pharmaceuticals Inc. Formulations and methods for treating ulcerative colitis
JOP20200068A1 (ar) 2017-09-26 2020-04-27 Nanomi B V طريقة لتحضير جسيمات دقيقة بواسطة تقنية مستحلب مزدوج
EP3720431B1 (en) 2017-12-06 2024-10-30 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2010115A1 (de) * 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
JPS523342B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1972-01-26 1977-01-27
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4341767A (en) * 1980-10-06 1982-07-27 Syntex Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
EP0190833B1 (en) * 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Method for producing microcapsule
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
IL79134A (en) * 1985-07-29 1991-06-10 American Cyanamid Co Continuous release peptide implants for parenteral administration
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5000886A (en) * 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5187150A (en) * 1987-10-14 1993-02-16 Debiopharm S.A. Polyester-based composition for the controlled release of polypeptide medicinal substances
CH672887A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1987-10-14 1990-01-15 Debiopharm Sa
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
EP0471036B2 (en) * 1989-05-04 2004-06-23 Southern Research Institute Encapsulation process
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
CH679207A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1989-07-28 1992-01-15 Debiopharm Sa
CH681425A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1990-11-14 1993-03-31 Debio Rech Pharma Sa
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.

Also Published As

Publication number Publication date
SE512670C2 (sv) 2000-04-17
GR1002548B (el) 1997-01-28
CA2074322A1 (en) 1993-01-23
PL298504A1 (en) 1994-01-10
US5445832A (en) 1995-08-29
NL194576C (nl) 2002-08-05
ES2037621A1 (es) 1993-06-16
GB2257973B (en) 1996-02-28
FI105318B (fi) 2000-07-31
LU88150A1 (fr) 1993-02-15
ITBS920092A1 (it) 1994-01-21
GB2257909A (en) 1993-01-27
JPH05221855A (ja) 1993-08-31
IE922367A1 (en) 1993-01-27
BE1005696A3 (fr) 1993-12-21
HRP920229A2 (en) 1996-04-30
SE9202213L (sv) 1993-01-23
RU2103994C1 (ru) 1998-02-10
CA2074320C (en) 1999-04-06
PT100712A (pt) 1993-10-29
GB2257973A (en) 1993-01-27
ZA925486B (en) 1993-04-28
FR2680109B1 (fr) 1994-09-02
ES2037621B1 (es) 1994-02-01
NL194576B (nl) 2002-04-02
MX9204268A (es) 1994-03-31
US5637568A (en) 1997-06-10
GB9215480D0 (en) 1992-09-02
CN1054543C (zh) 2000-07-19
NO304057B1 (no) 1998-10-19
ZA925485B (en) 1993-04-28
FI923320L (fi) 1993-01-23
FR2679450B1 (fr) 1995-06-09
FI106925B (fi) 2001-05-15
SI9200152A (en) 1993-03-31
ATA148992A (de) 1997-06-15
HUT64234A (en) 1993-12-28
IE922366A1 (en) 1993-01-27
DE9219084U1 (de) 1997-09-25
HU9301186D0 (en) 1993-07-28
CN1070344A (zh) 1993-03-31
CA2074320A1 (en) 1993-01-23
NO304136B1 (no) 1998-11-02
ITBS920093A0 (it) 1992-07-21
IL102590A0 (en) 1993-01-14
IL102591A0 (en) 1993-01-14
PT100712B (pt) 1999-07-30
DE4223284C2 (de) 1997-07-31
IL102590A (en) 1997-07-13
JP3600252B2 (ja) 2004-12-15
CH683592A5 (fr) 1994-04-15
PT100713A (pt) 1993-08-31
SI9200152B (sl) 1998-06-30
AU2043692A (en) 1993-01-28
CZ66093A3 (en) 1994-01-19
NO922886L (no) 1993-01-25
FR2680109A1 (fr) 1993-02-12
GB2257909B (en) 1996-01-10
IT1259892B (it) 1996-03-28
IT1259891B (it) 1996-03-28
ES2050070B1 (es) 1994-10-01
CA2074322C (en) 2003-04-08
CZ287585B6 (cs) 2000-12-13
CH683149A5 (fr) 1994-01-31
SK280612B6 (sk) 2000-05-16
UA35569C2 (uk) 2001-04-16
HU218203B (hu) 2000-06-28
GR1001446B (el) 1993-12-30
GR920100323A (el) 1993-05-24
IE69967B1 (en) 1996-10-16
JP2842736B2 (ja) 1999-01-06
NL9201309A (nl) 1993-02-16
DE4223284A1 (de) 1993-01-28
NL9201310A (nl) 1993-02-16
AT408609B (de) 2002-01-25
SE9202212L (sv) 1993-01-23
LU88151A1 (fr) 1993-02-15
DK176218B1 (da) 2007-02-26
ATA148892A (de) 2001-06-15
IL102591A (en) 1997-06-10
DK93892A (da) 1993-01-23
JPH06172208A (ja) 1994-06-21
SK38293A3 (en) 1993-08-11
NZ243643A (en) 1993-10-26
NO922885L (no) 1993-01-25
PH31564A (en) 1998-11-03
IE71199B1 (en) 1997-02-12
GB9215479D0 (en) 1992-09-02
NO922885D0 (no) 1992-07-21
NL194577C (nl) 2002-08-05
FR2679450A1 (fr) 1993-01-29
BE1005697A5 (fr) 1993-12-21
KR930702018A (ko) 1993-09-08
DK176219B1 (da) 2007-02-26
FI923320A0 (fi) 1992-07-21
DK93992D0 (da) 1992-07-21
FI923321A0 (fi) 1992-07-21
ITBS920093A1 (it) 1994-01-21
NO922886D0 (no) 1992-07-21
NL194577B (nl) 2002-04-02
AU652844B2 (en) 1994-09-08
BR9205375A (pt) 1994-03-08
EE03014B1 (et) 1997-08-15
ITBS920092A0 (it) 1992-07-21
PT100713B (pt) 1999-07-30
SE512609C2 (sv) 2000-04-10
DK93892D0 (da) 1992-07-21
FI923321L (fi) 1993-01-23
DK93992A (da) 1993-01-23
PL169387B1 (pl) 1996-07-31
DE4223282A1 (de) 1993-01-28
AU2043792A (en) 1993-01-28
SE9202213D0 (sv) 1992-07-21
TW260610B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-10-21
WO1993001802A1 (fr) 1993-02-04
ES2050070A1 (es) 1994-05-01
AT403348B (de) 1998-01-26
SE9202212D0 (sv) 1992-07-21

Similar Documents

Publication Publication Date Title
AU651711B2 (en) A composition for the sustained and controlled release of medicamentous substances and a process for preparing the same
AU3432689A (en) Controlled release composition
AU5112993A (en) Process for the preparation of drug pellets
AU1828988A (en) Controlled release formulation
AU2846492A (en) Process for preparing sintered shapes and compositions used therein
AU5018393A (en) Preparation of solid state materials
AU2746992A (en) Controlled release pharmaceutical compositions
GB2218905B (en) Controlled release pharmaceutical
AU3273989A (en) Ceramic foam and a process for forming the same
AU3405389A (en) Polyester fiber for industrial use and process for preparation thereof
AU4617689A (en) Composition for controlled release of polypeptides
AU3847189A (en) Ceramic material
AU2490492A (en) Process for the preparation of beta-phenylisoserine derivatives and use thereof
AU601640B2 (en) Oxetanocin-related compounds and process for producing same
EP0463833A3 (en) Controlled release pharmaceutical preparation and process for preparing same
AU646173B2 (en) 3-deoxy-mannosamine derivatives and process for their preparation
AU2846792A (en) Process for preparing sintered shapes and compositions for use therein
AU3502889A (en) Polymaleimide compounds and process for the preparation thereof
AU4062189A (en) Process for forming and using microdroplets
AU6685790A (en) Controlled release compositions and use
AU2000392A (en) Packaging material and methods of manufacturing and disposing of said material
AU4168789A (en) Granules for spreading and process for their preparation
AU7294491A (en) Labdanes and process for their preparation
AU4178189A (en) Therapeutic agent for aids and process for preparing it
AU4588593A (en) Process for the preparation of a polymer composition

Legal Events

Date Code Title Description
PC Assignment registered

Owner name: ZENTARIS AG

Free format text: FORMER OWNER WAS: ASTA MEDICA AG

HB Alteration of name in register

Owner name: ZENTARIS GMBH

Free format text: FORMER NAME WAS: ZENTARIS AG